RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value

$5.32−0.06 (-1.12%)

Close on Nov 13, 2026Market cap $221.28MP/E –Yield –

RxSight cash

Cash and short-term investments held at the end of each period.

RxSight's cash was $208.80M at Jun 30, 2026. For fiscal 2025 it was $228.10M, down 3.8% from the year before. The highest annual figure on record is $237.20M in fiscal 2024.

Annual cash

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$228.10M	-3.8%
FY2024	Dec 31, 2024	$237.20M	+86.5%
FY2023	Dec 31, 2023	$127.20M	+20.2%
FY2022	Dec 31, 2022	$105.80M	-33.6%
FY2021	Dec 31, 2021	$159.30M	+130.9%
FY2020	Dec 31, 2020	$69.00M	+681.4%
FY2019	Dec 31, 2019	$8.83M	–

Quarterly cash

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$208.80M	-8.2%
Q1 FY2026	Mar 31, 2026	$217.90M	-5.0%
Q4 FY2025	Dec 31, 2025	$228.10M	-3.8%
Q3 FY2025	Sep 30, 2025	$227.50M	-4.0%
Q2 FY2025	Jun 30, 2025	$227.50M	-2.4%
Q1 FY2025	Mar 31, 2025	$229.30M	+82.9%
Q4 FY2024	Dec 31, 2024	$237.20M	+86.5%
Q3 FY2024	Sep 30, 2024	$237.10M	+79.8%
Q2 FY2024	Jun 30, 2024	$233.20M	+58.5%
Q1 FY2024	Mar 31, 2024	$125.40M	-18.5%
Q4 FY2023	Dec 31, 2023	$127.20M	+20.2%
Q3 FY2023	Sep 30, 2023	$131.90M	+16.9%
Q2 FY2023	Jun 30, 2023	$147.10M	+14.4%
Q1 FY2023	Mar 31, 2023	$153.90M	+7.0%
Q4 FY2022	Dec 31, 2022	$105.80M	-33.6%
Q3 FY2022	Sep 30, 2022	$112.80M	-33.0%
Q2 FY2022	Jun 30, 2022	$128.60M	+108.4%
Q1 FY2022	Mar 31, 2022	$143.80M	+478.8%
Q4 FY2021	Dec 31, 2021	$159.30M	+130.9%
Q3 FY2021	Sep 30, 2021	$168.30M	+1208.4%
Q2 FY2021	Jun 30, 2021	$61.70M	+361.7%
Q1 FY2021	Mar 31, 2021	$24.85M	+181.4%
Q4 FY2020	Dec 31, 2020	$69.00M	–
Q3 FY2020	Sep 30, 2020	$12.86M	–
Q2 FY2020	Jun 30, 2020	$13.36M	–
Q4 FY2019	Dec 31, 2019	$8.83M	–